长春高新：子公司注射用GenSci143临床试验申请获美国FDA批准

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical, received written notification from the FDA regarding the approval of the clinical trial application for GenSci143, a therapeutic biological product intended for the treatment of advanced solid tumors such as prostate cancer and lung cancer [1] Group 1 - The FDA approval pertains to the clinical trial application for GenSci143, which is classified as a Class 1 therapeutic biological product [1] - GenSci143 is designed for the treatment of multiple advanced solid tumors, including prostate cancer and lung cancer [1]